Although cardiometabolic risks associated with hormonal therapies are well-studied, research on lifestyle factors in hormone-dependent breast cancer (BC) patients remains scarce.
Objective
The aim was to evaluate and compare lifestyle and cardiometabolic markers in tamoxifen (TAM) or aromatase inhibitors (AIs) treated BC patients.
Methods
A total of 132 hormone-dependent BC patients, aged 55 ± 11 years, receiving TAM or AIs, underwent comprehensive metabolic assessments, including anthropometric parameters, daily energy intake, physical activity levels, dietary quality (MEDAS index), and cardiometabolic markers.
Results
AIs patients had higher body mass index (BMI), waist circumference (WC), and daily energy intake, with lower energy expenditure and physical activity, compared to TAM patients (p < 0.05). Both groups had unbalanced diets, high in simple carbohydrates and saturated fats, with significantly lower Mediterranean diet (MD) adherence in AIs group (p < 0.05). After adjustment for confounding factors, only associations with total cholesterol (TC) (β = 0.48, p < 0.001), LDL-C (β = 0.52, p < 0.001), and TC/HDL-C and LDL-C/HDL-C ratios remained significant. Additionally, correlations were found between hormone therapy duration and TC (r = 0.227, p = 0.009), LDL-C (r = 0.184, p = 0.03), BMI (r = 0.219, p = 0.01), and WC (r = 0.166, p = 0.05).
Conclusion
Our findings support the hypothesis that lifestyle parameters, in interaction with hormonal treatments, may exacerbate cardiometabolic risk in breast cancer patients. These observations underscore the importance of comprehensive management that addresses lifestyle-related factors.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
2.
ChamalidouCNasicSLinderholmB. Compliance to adjuvant endocrine therapy and survival in breast cancer patients. Cancer Treat Res Commun2023 Apr; 35: 100704.
3.
OkwuosaTMMorgansARheeJ-W, et al.Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association. Circ Genom Precis Med2021; 14: e000082.
4.
MiziakPBaranMBłaszczakE, et al.Estrogen receptor signaling in breast cancer. Cancers (Basel)2023; 15: 4689.
5.
JayasekeraJZhaoASchechterC, et al.Reassessing the benefits and harms of risk-reducing medication considering the persistent risk of breast cancer mortality in estrogen receptor–positive breast cancer. J Clin Oncol2023; 41: 859–870.
6.
BércziBFarkasNHegyiP, et al.Aromatase inhibitors and plasma lipid changes in postmenopausal women with breast cancer: a systematic review and meta-analysis. J Clin Med2024; 13: 1818.
7.
YooJ-JJungE-AKimZ,et al.Risk of cardiovascular events and lipid profile change in patients with breast cancer taking aromatase inhibitor: a systematic review and meta-analysis. Curr Oncol2023; 30: 1831–1843.
8.
MelicharBKalábováHKrčmováL, et al.Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res2009 Aug; 29: 3337–3346.
9.
AlomarSAGămanM-APrabaharK, et al.The effect of tamoxifen on the lipid profile in women: a systematic review and meta-analysis of randomized controlled trials. Exp Gerontol2022; 159: 111680.
10.
WangWLiuX. Comparison of effects of tamoxifen and Toremifene on hepatic function and serum lipids in breast cancer patients during adjuvant endocrine therapy. Anticancer Drugs2024; 35: 371–376.
11.
Rillamas-SunEKwanMLIribarrenC, et al.Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Res Sq2023 Mar; 22: rs.3.rs-2675372.
12.
KimJ-EChoiJParkJ, et al.Effects of endocrine therapy on cardiovascular diseases and type 2 diabetes among breast cancer survivors: the national health insurance service database of Korea. J Am Heart Assoc2022; 11: e026743.
13.
SuriMFKQureshiAI. Prehypertension as a risk factor for cardiovascular diseases. J Cardiovasc Nurs2006; 21: 478–482.
14.
OhSLeeJHongYS,et al.Increased risk of cardiovascular disease associated with diabetes among adult cancer survivors: a population-based matched cohort study. Eur J Prev Cardiol2023; 30: 670–679.
15.
MerklerMReinerŽ. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol2007; 21: 1–3.
16.
MasoodADastgirNRehmanIU, et al.Interaction of tobacco abuse with other conventional risk factors of cardiovascular risk - synergistic impact or an independent menace?Pak Heart J2022 Jan; 54: 352–356.
17.
Rizwan SajidMMuhammadNShahbazA,et al.A statistical study on the prevalence of physical inactivity among cardiovascular diseases patients: the predictive role of demographic and socioeconomic factors. Res J Pharm Technol2021; 14: 3679–3684.
18.
LaheyRKhanSS. Trends in obesity and risk of cardiovascular disease. Curr Epidemiol Rep2018; 5: 243–251.
19.
PetersenKSKris-EthertonPM. Diet quality assessment and the relationship between diet quality and cardiovascular disease risk. Nutrients2021; 13: 4305.
20.
GradisharWJAndersonBOBalassanianR, et al.Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl ComprCancNetw2018; 16: 310–320.
EstruchRRosESalas-SalvadóJ, et al.Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med2013; 368: 1279–1290.
24.
FriedewaldWTLevyRIFredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem1972; 18: 499–502.
25.
HaiderGShaikhZKumarP, et al.Effect of tamoxifen on plasma lipid profile in patients of breast cancer. J Ayub Med Coll Abbottabad2023; 35: 558–562.
26.
LinCChenL-SKuoS-J,et al.Adjuvant tamoxifen influences the lipid profile in breast cancer patients. Breast Care2014; 9: 35–39.
27.
GuptaSTandonVRKapoorB, et al.Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer. J Assoc Physicians India2006 Mar; 54: 183–186.
28.
GaibarMFernándezGRomero-LorcaA, et al.Tamoxifen therapy in breast cancer: do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?Int J Biol Markers2013; 28: 371–376.
29.
MarkopoulosCJTsarouchaAKGogasHJ. Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients. Clin Lipidol2010; 5: 245–254.
30.
ZhangZYangQJinM, et al.Tamoxifen upregulates the peroxisomal β-oxidation enzyme Enoyl CoA hydratase and 3-hydroxyacyl CoA hydratase ameliorating hepatic lipid accumulation in mice. Int J Biochem Cell Biol2024; 172: 106585.
31.
HerringtonDMKleinKP. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues2001; 11: 95–102.
32.
MazzuttiFSCustódioIDDLimaMTM, et al.Breast cancer survivors undergoing endocrine therapy have a worrying risk factor profile for cardiovascular diseases. Nutrients2021; 13: 1114.
33.
GantenbeinKVKanaka-GantenbeinC. Mediterranean diet as an antioxidant: the impact on metabolic health and overall wellbeing. Nutrients2021; 13: 1951.
34.
WangDDNguyenLHLiY, et al.The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk. Nat Med2021; 27: 333–343.
35.
Guasch-FerréMWillettWC. The Mediterranean diet and health: a comprehensive overview. J Intern Med2021; 290: 549–566.
36.
AugimeriGMontaltoFIGiordanoC, et al.Nutraceuticals in the Mediterranean diet: potential avenues for breast cancer treatment. Nutrients2021; 13: 2557.
37.
HillJOWyattHRPetersJC. Energy balance and obesity. Circulation2012; 126: 126–132.
38.
FairAMMontgomeryK. Energy balance, physical activity, and cancer risk. Methods Mol Biol2009; 472: 57–88.
39.
BlairSNHandGAHillJO. Energy balance: a crucial issue for exercise and sports medicine. Br J Sports Med2015; 49: 970–971.
40.
BaumannFTBlochWWeissenA, et al.Physical activity in breast cancer patients during medical treatment and in the aftercare - a review. Breast Care2013; 8: 330–334.
41.
SestakIHarvieMHowellA, et al.Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Res Treat2012; 134: 727–734.
42.
UhelskiARBlackfordALShengJY, et al.Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer. J Cancer Surviv2024; 18: 1683–1696.
43.
ScalzoRLForightRMHullSE, et al.Breast cancer endocrine therapy promotes weight gain with distinct adipose tissue effects in lean and obese female mice. Endocrinology2021; 162: bqab174.
44.
BrynesAEEdwardsCMGhateiMA, et al.A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men. Br J Nutr2003; 89: 207–218.
45.
ParksEJHellersteinMK. Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am J Clin Nutr2000; 71: 412–433.
46.
KnoppRHRetzlaffBWaldenC, et al.One-Year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. Proc Soc Exp Biol Med2000; 225: 191–199.
47.
GuayVLamarcheBCharestA, et al.Effect of short-term low- and high-fat diets on low-density lipoprotein particle size in normolipidemic subjects. Metabolism2012; 61: 76–83.
48.
ZdericTWHamiltonMT. Physical inactivity amplifies the sensitivity of skeletal muscle to the lipid-induced downregulation of lipoprotein lipase activity. J Appl Physiol2006; 100: 249–257.
